Genta Incorporated (GNTA/GNTA.OB) Wrap Up:

Genta Incorporated operates as a biopharmaceutical company with a diversified product portfolio that is focused on delivering products for the treatment of patients with cancer. Its research portfolio consists of two programs, DNA/RNA Medicines and Small Molecules. The company's lead compound from its DNA/RNA Medicines program is Genasenseâ (oblimersen sodium) injection that is designed to block the production of a protein, known as Bcl-2, which is a fundamental cause of the inherent resistance of cancer cells to anticancer treatments, such as chemotherapy, radiation, and monoclonal antibodies. Genta Incorporated is recruiting patients to the AGENDA Trial, a global Phase III trial of Genasen...